{
    "organizations": [],
    "uuid": "1b1167d3c70191641f2ed1373903d4b3b385b10c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-fda-accepts-novartis-submission-of/brief-fda-accepts-novartis-submission-of-biosimilar-version-of-humira-idUSFWN1PA0O9",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA accepts Novartis submission of biosimilar version of Humira",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 16, 2018 / 6:07 AM / Updated 12 minutes ago BRIEF-FDA accepts Novartis submission of biosimilar version of Humira Reuters Staff \nJan 16 (Reuters) - Novartis AG: \n* SANDOZ REGULATORY SUBMISSION FOR PROPOSED BIOSIMILAR ADALIMUMAB ACCEPTED BY FDA \n* US FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTED ITS BIOLOGICS LICENSE APPLICATION (BLA), SUBMITTED UNDER THE 351 (K) PATHWAY, FOR PROPOSED BIOSIMILAR ADALIMUMAB TO THE REFERENCE MEDICINE, HUMIRA \n* ‍DATA PACKAGE PROVIDED IS EXPECTED TO DEMONSTRATE THAT SANDOZ PROPOSED BIOSIMILAR ADALIMUMAB MATCHES REFERENCE BIOLOGIC MEDICINE IN TERMS OF SAFETY, EFFICACY AND QUALITY​ Source text for Eikon: Further company coverage: (Reporting By Michael Shields)",
    "published": "2018-01-16T08:06:00.000+02:00",
    "crawled": "2018-01-16T08:28:30.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "updated",
        "minute",
        "ago",
        "accepts",
        "novartis",
        "submission",
        "biosimilar",
        "version",
        "humira",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "novartis",
        "ag",
        "sandoz",
        "regulatory",
        "submission",
        "proposed",
        "biosimilar",
        "adalimumab",
        "accepted",
        "fda",
        "u",
        "food",
        "drug",
        "administration",
        "fda",
        "accepted",
        "biologics",
        "license",
        "application",
        "bla",
        "submitted",
        "k",
        "pathway",
        "proposed",
        "biosimilar",
        "adalimumab",
        "reference",
        "medicine",
        "humira",
        "package",
        "provided",
        "expected",
        "demonstrate",
        "sandoz",
        "proposed",
        "biosimilar",
        "adalimumab",
        "match",
        "reference",
        "biologic",
        "medicine",
        "term",
        "safety",
        "efficacy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "michael",
        "shield"
    ]
}